Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROCODONE BITARTRATE AND IBUPROFEN vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Short-term (up to 10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Hydrocodone: 3.8-4.5 hours (immediate release); Ibuprofen: 1.8-2.5 hours (racemic, S-enantiomer slightly shorter). Clinical context: dosing every 4-6 hours due to hydrocodone half-life.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Hydrocodone is primarily metabolized by CYP3A4 and CYP2D6 enzymes to hydromorphone (active) and norhydrocodone (inactive). Ibuprofen is metabolized by CYP2C9 to inactive metabolites (hydroxyibuprofen and carboxyibuprofen).
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Hydrocodone: primarily renal (60-70% as metabolites, <12% unchanged); Ibuprofen: primarily renal (90% as metabolites and conjugates, <1% unchanged), minor biliary/fecal.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Hydrocodone: ~19% bound to plasma proteins; Ibuprofen: >99% bound to albumin.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
Hydrocodone: 3.3-4.7 L/kg; Ibuprofen: 0.1-0.2 L/kg. High Vd for hydrocodone indicates extensive tissue distribution; low Vd for ibuprofen indicates plasma and interstitial fluid confinement.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Hydrocodone: mean absolute bioavailability ~70-80% (oral); Ibuprofen: ~80-100% (oral, rapid absorption).
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
GFR 30-60 m L/min: Use with caution, consider reducing dose or increasing interval. GFR <30 m L/min: Not recommended due to accumulation of ibuprofen and hydrocodone metabolites.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Child-Pugh Class B: Start with lowest possible dose, monitor closely. Child-Pugh Class C: Contraindicated due to risk of toxicity.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Not recommended for use in pediatric patients; safety and efficacy not established.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Initiate with lowest effective dose (e.g., half tablet) and monitor for CNS and respiratory depression; reduce maximum daily dose to 4 tablets due to increased sensitivity and renal impairment.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from ibuprofen (NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation, which can be fatal).
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity; gastrointestinal bleeding, ulceration, and perforation; cardiovascular thrombotic events; hypertension; renal toxicity; anaphylactoid reactions; serious skin reactions; use in pregnancy; use in breastfeeding; use in hepatic impairment; use in renal impairment; use in elderly; use in patients with bleeding disorders.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction; hypersensitivity to hydrocodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain relief in the setting of coronary artery bypass graft (CABG) surgery; use within 14 days of monoamine oxidase inhibitor (MAOI) therapy.
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Grapefruit and grapefruit juice may increase hydrocodone levels and risk of adverse effects; avoid concurrent use. Alcohol potentiates CNS depression and increases GI bleeding risk; avoid altogether. High-fat meals may delay absorption of hydrocodone, but clinical impact is minimal; take consistently with or without food.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
Pregnancy Category C: No adequate studies in pregnant women. Ibuprofen (NSAID) is associated with increased risk of premature closure of ductus arteriosus and oligohydramnios in third trimester; avoid after 30 weeks gestation. Hydrocodone may cause respiratory depression in neonate if used near term; chronic use may lead to neonatal opioid withdrawal syndrome. First trimester: limited data, but NSAIDs may increase risk of miscarriage; hydrocodone not associated with major malformations. Second trimester: generally considered safer, but risks remain. Third trimester: avoid NSAIDs; hydrocodone use only if benefit outweighs risk.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Limited data; both drugs excreted into breast milk. Ibuprofen M/P ratio ~0.01, considered compatible. Hydrocodone M/P ratio ~2.0; low levels in milk but risk of infant sedation and respiratory depression. Use caution; monitor infant for drowsiness, difficulty breastfeeding. American Academy of Pediatrics considers hydrocodone as 'usually compatible' but avoid when possible. Alternatives preferred.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
No specific pharmacokinetic studies; however, pregnancy increases clearance and volume of distribution for both drugs. Ibuprofen: dose adjustments not typically recommended, but due to renal effects and fetal risks, use lowest effective dose for shortest duration. Hydrocodone: increased clearance may require higher doses to achieve analgesic effect; consider patient-specific titration. However, due to neonatal risks, minimize use and duration.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Hydrocodone/ibuprofen combines an opioid agonist with an NSAID. Be aware of additive risks: respiratory depression, sedation, GI bleeding, renal impairment, and cardiovascular thrombotic events. Avoid in patients with severe asthma, GI obstruction, or after recent bariatric surgery. Use lowest effective dose for shortest duration. Monitor for serotonin syndrome if used with other serotonergic drugs. Abrupt discontinuation after prolonged use may cause withdrawal.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Hydrocodone can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, other opioids) while taking this medication.,Ibuprofen may increase risk of stomach bleeding; report black/tarry stools, coffee-ground vomit, or abdominal pain.,Avoid other NSAIDs (e.g., aspirin, naproxen) or COX-2 inhibitors to prevent additive GI and renal toxicity.,Store securely away from children and others; dispose of unused medication via take-back programs.,Do not abruptly stop after long-term use; withdrawal symptoms may occur (anxiety, sweating, nausea).
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROCODONE BITARTRATE AND IBUPROFEN vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
HYDROCODONE BITARTRATE AND IBUPROFEN is a NSAID that works by Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROCODONE BITARTRATE AND IBUPROFEN and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROCODONE BITARTRATE AND IBUPROFEN is: One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HYDROCODONE BITARTRATE AND IBUPROFEN and ACETAMINOPHEN AND IBUPROFEN. Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HYDROCODONE BITARTRATE AND IBUPROFEN is classified as Category D/X. Pregnancy Category C: No adequate studies in pregnant women. Ibuprofen (NSAID) is associated with increased risk of premature closure of ductus arteriosus and oligohydramnios in th. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.